NLS Pharmaceutics ( (NLSP) ) has issued an announcement.
NLS Pharmaceutics and Kadimastem have filed a Registration Statement with the SEC in preparation for a proposed merger, creating a Nasdaq-traded biotechnology entity. This merger aims to leverage NLS’s and Kadimastem’s strengths, enhancing market position and shareholder value by focusing on advanced clinical development and expanding cell therapy platforms.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on innovative therapies for rare and complex central nervous system disorders. Kadimastem Ltd. is an Israeli clinical-stage cell therapy company developing allogeneic cell products for neurodegenerative diseases and diabetes.
YTD Price Performance: -92.29%
Average Trading Volume: 385,202
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.5M
For a thorough assessment of NLSP stock, go to TipRanks’ Stock Analysis page.